Skip to main content
. 2017 Apr 13;8(31):50747–50760. doi: 10.18632/oncotarget.17096

Figure 5. CUR blocks migration and tubule formation of HUVECs in vitro.

Figure 5

(A–B) CUR significantly inhibited HUVECs migration, as evidenced by a decrease in the number of crystal violet-stained cells. 10 μM CUR pretreatment of HUVECs inhibited transmigration, which was statistically significant difference to the effect of control group (scale bars, 10 μm). (C–D) HUVECs were seeded in 96-well culture plates precoated with Matrigel; and then examined for tubule formation using an inverted microscope. Tubule formation was markedly decreased in a dose-dependent manner in CUR-treated cells (scale bars, 100 μm). (E) Results of wound healing assay, HUVECs migration ratio after CUR treatment for 8 hours. (F) HUVECs were treated with or without CUR at the indicated concentrations, followed by assessment for cell viability using MTT assays. Raw data from MTT assays were normalized to the % of viable cells in control versus CUR-treated carcinoma cells. (G–K) HUVECs were treated with CUR for 24 hours, then cell lysates were collected and western blot was conducted for the indicated proteins (**P < 0.01 vs control).